

Special Issue

Biomarkers in Dementia Disorders

Message from the Guest Editors

Alzheimer's disease, the most common type of neurodegenerative dementia, is characterized by two main pathological features: extracellular accumulation of amyloid beta peptides in the form of amyloid plaques and hyperphosphorylation of tau protein. Most frontotemporal lobar degenerations are due to tau or TDP-43 pathology, while a small percentage is due to FUS or more rare pathologies. Parkinson's disease with or without dementia and dementia with Lewy bodies belong to the group of synucleinopathies. Thus, neurodegenerative dementia disorders are currently viewed as proteinopathies, being characterized by the aggregation of one or more protein(s) or peptides. Some of these proteins can be quantified in the CSF or plasma (or other fluids) and serve not only as biomarkers of various biochemical processes but also as important diagnostic tools. The accumulation of amyloid beta peptides and/or tau in the brain can also be studied with positron emission tomography. Fluid or imaging biomarkers may also be helpful in the diagnosis of secondary causes of dementia. This Special Issue will highlight the latest advances in fluid and imaging biomarkers for dementia disorders.

Guest Editors

Dr. George P. Paraskevas

Second Department of Neurology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece

Dr. Vasilios C. Constantinides

1st Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Deadline for manuscript submissions

closed (31 July 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/121794

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).